BLUE Stock Recent News

NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating bluebird bio, Inc. (Nasdaq: BLUE ), relating to the proposed merger with Beacon Parent Holdings, L.P.

PHILADELPHIA, PA / ACCESS Newswire / February 21, 2025 / Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by "funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced biotech executives.

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating bluebird (Nasdaq: BLUE) for possible breaches of fiduciary duty and other violations of law in its transaction with Carlyle and SK Capital. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, bluebird stockholders will receive only $3.00 per share in cash and a contingent va.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ: BLUE) to Carlyle Group and SK Capital Partners, LP is fair to bluebird shareholders. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird's current product portfolio achieves $600 million in.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”) in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will provide bluebird prim.

Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health plans are looking at how to create a new risk pool arrangement to help manage the costs of the therapies.

Kia EV9 named "Best 3-Row Electric Vehicle" for the second consecutive year Kia Telluride recognized as the "Best Midsize SUV" for sixth straight year – setting a KBB record for the most wins in this category by the same model IRVINE, Calif. , Feb. 10, 2025 /PRNewswire/ -- Two Kia SUVs are once again the recipients of Kelley Blue Book Best Buy Awards.

The documentary, from Bad Robot, Glen Powell's Barnstorm Productions, Zipper Bros Films, IMAX Entertainment and Dolphin Entertainment, follows a year in the life of the Blue Angels from training through touring, filmed with awe-inspiring IMAX-certified digital cameras. Reformatted specifically for IMAX screens, this newly abridged version will be offered in breathtaking IMAX 3D presentation.

Bluebird Bio (BLUE, Financial) experienced a significant drop in its stock price, declining by 5.67%. The shares are currently trading at $0.491, with a trading volume of 3.72 million shares, a turnover rate of 1.92%, and showing a price amplitude of 4.76%.

Bluebird Bio (BLUE, Financial) stock experienced a notable surge of 5.04% to $0.494 per share. The trading volume reached 6.47552 million shares, resulting in a turnover rate of 3.34% and a volatility of 8.69%.